Optics and Quantum Electronics

Contains table of contents for Section 3 and reports on twenty-three research projects.Joint Services Electronics Program Contract DAAL03-92-C-0001U.S. Air Force - Office of Scientific Research Contract F49620-91-C-0091Charles S. Draper Laboratories Contract DL-H-441629MIT Lincoln LaboratoryNational Science Foundation Grant ECS 90-12787Fujitsu LaboratoriesU.S. Navy - Office of Naval Research Grant N00014-92-J-1302National Center for Integrated PhotonicsNational Center for Integrated Photonics TechnologyNational Science Foundation Grant EET 88-15834Joint Services Electronics Program Contract DAAL03-91-C-0001National Science Foundation Fellowship ECS-85-52701U.S. Navy - Office of Naval Research (MGH) Contract N00014-91-C-0084U.S. Navy - Office of Naval Research Grant N00014-91-J-1956National Institutes of Health Grant NIH-5-RO1-GM35459-08Bose CorporationLawrence Livermore National Laboratories Subcontract B160530U.S. Department of Energy Grant DE-FG02-89-ER14012Rockwell International CorporationSpace Exploration AssociatesFuture Energy Applied Technology, Inc

Optics and Quantum Electronics

Contains table of contents for Section 3, reports on twenty-one research projects and a list of publications and meeting papers.Joint Services Electronics Program Contract DAAL03-92-C-0001U.S. Air Force - Office of Scientific Research Contract F49620-91-C-0091Charles S. Draper Laboratories Contract DL-H-441692MIT Lincoln LaboratoryNational Science Foundation Grant ECS 90-12787Fujitsu LaboratoriesU.S. Navy - Office of Naval Research Grant N00014-92-J-1302National Center for Integrated Photonic TechnologyNational Science Foundation Grant ECS 85-52701U.S. Navy - Office of Naval Research (MFEL) Grant N00014-91-C-0084U.S. Navy - Office of Naval Research (MFEL) Grant N00014-91-J-1956National Institutes of Health Grant R01-GM35459-08U.S. Air Force - Office of Scientific Research Grant F49620-93-1-0301MIT Lincoln Laboratory Contract BX-5098Electric Power Research Institute Contract RP3170-2

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Examining differences in psychological adjustment problems among children conceived by assisted reproductive technologies

The aim of this study was to examine whether there was variation in levels of psychological adjustment among children conceived through Assisted Reproductive Technologies using the parents' gametes (homologous), sperm donation, egg donation, embryo donation and surrogacy. Information was provided by parents about the psychological functioning of 769 children aged 5 to 9 years who had been born using ART (from the five groups described). Comparisons were made between the different conception groups, to UK national norms and, for a sub-sample of multiple births, to an age-matched twin sample. No differences were found between the conception groups except that fathers from the egg donation group rated children higher in conduct problems compared to other ART groups. No effects were observed by ART treatment type (ICSI vs. IVF, GIFT and IUI). There was some evidence of lower conduct problems and prosocial behaviour among children conceived through homologous IVF compared to national norms. Taken together, however, consistent differences between groups and in comparison to naturally conceived children were not apparent for mother- or father-rated adjustment problems. Children conceived with assisted reproductive technologies, regardless of whether they are genetically related or unrelated to their parents or born by gestational surrogacy do not differ in their levels of psychological adjustment. Nor do they appear to be at greater risk of psychological adjustment problems in middle childhood compared to naturally conceived children. © 2009 The International Society for the Study of Behavioural Development

Reconstructing prehistoric African population structure

We assembled genome-wide data from 16 prehistoric Africans. We show that the anciently divergent lineage that comprises the primary ancestry of the southern African San had a wider distribution in the past, contributing approximately two-thirds of the ancestry of Malawi hunter-gatherers ∼8,100–2,500 years ago and approximately one-third of the ancestry of Tanzanian hunter-gatherers ∼1,400 years ago. We document how the spread of farmers from western Africa involved complete replacement of local hunter-gatherers in some regions, and we track the spread of herders by showing that the population of a ∼3,100-year-old pastoralist from Tanzania contributed ancestry to people from northeastern to southern Africa, including a ∼1,200-year-old southern African pastoralist. The deepest diversifications of African lineages were complex, involving either repeated gene flow among geographically disparate groups or a lineage more deeply diverging than that of the San contributing more to some western African populations than to others. We finally leverage ancient genomes to document episodes of natural selection in southern African populations.P.S. was supported by the Wenner-Gren Foundation and the Swedish Research Council (VR grant 2014-453). J.C.T was supported by a grant from the Program for the Enhancement of Research at Emory University. J.K. and A.M. were supported by the DFG grant KR 4015/1-1 and the Max Planck Society. K.Si. was supported by NSF grant BCS-1613577. M.Ha., A.H., M.Me., and S.P. were supported by the Max Planck Society. A.G.M. and J.P. were supported by the National Research Foundation of South Africa. R.R. was supported by the South African Medical Research Council. N.B. was supported by ERC starting grant SEALINKS (206148), and R.P. was supported by ERC starting grant ADNABIOARC (263441). M.G.T. was supported by Wellcome Trust Senior Investigator Award (grant number 100719/Z/12/Z). D.R. was supported by NIH grant GM100233 and by NSFHOMINID BCS-1032255 and is a Howard Hughes Medical Institute investigator. The laboratory at Penn State was supported by the NSF Archaeometry program (BCS-1460369, D.J.K.).http://www.cell.com2018-09-21hj2017Anthropology and ArchaeologySchool of Health Systems and Public Health (SHSPH